Bausch Health Companies Inc. (TSX: BHC)
Market Cap | 3.97B |
Revenue (ttm) | 12.80B |
Net Income (ttm) | -240.47M |
Shares Out | n/a |
EPS (ttm) | -0.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 49,973 |
Average Volume | 203,399 |
Open | 10.80 |
Previous Close | 10.77 |
Day's Range | 10.65 - 10.88 |
52-Week Range | 5.45 - 15.43 |
Beta | 0.75 |
RSI | 47.67 |
Earnings Date | Feb 20, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in... [Read more]
Financial Performance
In 2023, Bausch Health Companies's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 163.1% more than in 2022.
Financial numbers in USD Financial StatementsNews
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, Febr...
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conferen...
Bausch Health Swaps Out Advisers After Years of Debt, Sale Talks
Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long effort to tackle some of its approximately $20 billion dollars of debt and enabl...
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarte...
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for...
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan
Bausch + Lomb CEO on the negative impact of screen time on eye health
Brent Saunders, Bausch and Lomb CEO, discusses how too much screen time can have a negative impact on vision.
Bausch and Lomb CEO: Right on track with our important initiatives
Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.
Bausch and Lomb CEO: Right on track with our important initiatives
Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate h...
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial...
InflammX Therapeutics Announces Option Agreement with Bausch + Lomb
TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet...
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine
JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health ...
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered...
Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb
BOSTON--(BUSINESS WIRE)--Outcome's expertise in corporate strategy, financing, and transaction execution helped position ELIOS as a key innovator in glaucoma treatment market.
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundati...
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman ...
Contact lens maker Bausch + Lomb says it is exploring sale
Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company.
Bausch & Lomb edges higher after confirming sales process
Bausch & Lomb (BLCO) confirms sales process for eyecare company, exploring potential sale options as part of full separation from Bausch Health Companies...
Bausch Health Companies Inc (BHC) Responds to Potential Sale Rumors
Bausch Health Companies Inc (BHC) Responds to Potential Sale Rumors
Bausch + Lomb Responds to Rumors of a Potential Sale
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement...
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a...
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Wednesday.
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affili...